KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Free Cash Flow (2016 - 2025)

Vertex Pharmaceuticals has reported Free Cash Flow over the past 17 years, most recently at $348.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $348.6 million for Q4 2025, down 29.15% from a year ago — trailing twelve months through Dec 2025 was $3.2 billion (up 504.13% YoY), and the annual figure for FY2025 was $3.2 billion, up 504.13%.
  • Free Cash Flow for Q4 2025 was $348.6 million at Vertex Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over the last five years, Free Cash Flow for VRTX hit a ceiling of $1.3 billion in Q3 2024 and a floor of -$3.8 billion in Q2 2024.
  • Median Free Cash Flow over the past 5 years was $897.0 million (2022), compared with a mean of $603.7 million.
  • Biggest five-year swings in Free Cash Flow: soared 535.3% in 2022 and later plummeted 455.66% in 2024.
  • Vertex Pharmaceuticals' Free Cash Flow stood at $933.2 million in 2021, then grew by 11.96% to $1.0 billion in 2022, then tumbled by 83.11% to $176.5 million in 2023, then soared by 178.75% to $492.0 million in 2024, then dropped by 29.15% to $348.6 million in 2025.
  • The last three reported values for Free Cash Flow were $348.6 million (Q4 2025), $1.1 billion (Q3 2025), and $927.4 million (Q2 2025) per Business Quant data.